In addition to classical immune checkpoints such as CTLA‐4 and PD‐1, as well as metabolism‐related molecules such as CD39/CD73, the chemokine receptor CCR8 has emerged as a highly promising therapeutic target because of its specific expression in tumor‐infiltrating Tregs (TI‐Tregs).[258, 259]. The gene discussed is CCR8; the disease is neoplasm.